scholarly journals Early Blood Glucose Level Post-Admission Correlates with the Outcomes and Oxidative Stress in Neonatal Hypoxic-Ischemic Encephalopathy

Antioxidants ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 39
Author(s):  
Inn-Chi Lee ◽  
Jiann-Jou Yang ◽  
Ying-Ming Liou
Keyword(s):  
Blood Glucose ◽  
Glucose Level ◽  
Clinical Staging ◽  
Mri Findings ◽  
Neurodevelopmental Outcomes ◽  
Glucose Levels ◽  
Group 3 ◽  
Group 2 ◽  
Poor Outcomes ◽  
Group 1

The antioxidant defense system is involved in the pathogenesis of neonatal hypoxic-ischemic encephalopathy (HIE). To analyze the relationship between first serum blood glucose levels and outcomes in neonatal HIE, seventy-four patients were divided, based on the first glucose level, into group 1 (>0 mg/dL and <60 mg/dL, n =11), group 2 (≥60 mg/dL and <150 mg/dL, n = 49), and group 3 (≥150 mg/dL, n = 14). Abnormal glucose levels had poor outcomes among three groups in terms of the clinical stage (p = 0.001), brain parenchymal lesion (p = 0.004), and neurodevelopmental outcomes (p = 0.029). Hearing impairment was more common in group 3 than in group 1 (p = 0.062) and group 2 (p = 0.010). The MRI findings of group 3 exhibited more thalamus and basal ganglion lesions than those of group 1 (p = 0.012). The glucose level was significantly correlated with clinical staging (p< 0.001), parenchymal brain lesions (p = 0.044), hearing impairment (p = 0.003), and neurodevelopmental outcomes (p = 0.005) by Pearson’s test. The first blood glucose level in neonatal HIE is an important biomarker for clinical staging, MRI findings, as well as hearing and neurodevelopment outcomes. Hyperglycemic patients had a higher odds ratio for thalamus, basal ganglia, and brain stem lesions than hypoglycemic patients with white matter and focal ischemic injury. Hyperglycemia can be due to prolonged or intermittent hypoxia and can be associated with poor outcomes.

scholarly journals Comparing the effect of ladies’ finger water with fenugreek seeds water on the blood glucose level among subjects with type 2 diabetes mellitus-a randomized controlled trial

2021 ◽  
Vol 8 (1) ◽  
pp. 10
Author(s):  
Radhika R. ◽  
Navaneetha M. ◽  
Ravichandran K. ◽  
Hemavathi P.
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Glucose Level ◽  
Fenugreek Seeds ◽  
Significant Difference ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

<p><strong>Background: </strong>The primary aim of managing diabetes is to maintain blood glucose level to prevent diabetes induced complications. Studies showed that ladies finger and fenugreek seeds are blood sugar stabilizer. The objective of this randomized active controlled trial was to assess the effect of ladies finger water versus fenugreek seeds water on the blood glucose level among subject with type 2 diabetes.</p><p><strong>Methods: </strong>Total of 180 study participants were selected and equally assigned to three groups by computer generated randomization. Group 1-received ladies finger water and oral antidiabetic drug (OAD); group 2-received fenugreek seeds water and OAD; group 3-received only OAD for 15 days. Pre and post intervention fasting blood sugar (FBS) was assessed by accu-chek Performa glucometer. Wilcoxon signed rank test; one-way analysis of covariance followed by post hoc test with Bon-ferroni correction was done.</p><p><strong>Results: </strong>Analysis was done based on 168 subjects. There was a significant reduction in FBS level with the mean difference of group 1-21.0 mg/dl (p&lt;0.001), group 2-20.3 mg/dl (p&lt;0.001) and group 3-4.7 mg/dl (p=0.068). No significant difference found between group 1 and group 2 (p=1.00), but significant difference found between group 1 and group 3 (p=0.032); group 2 and group 3 (p=0.012). Both ladies finger water and fenugreek seeds water were superior in reduction of FBS than OAD.</p><p><strong>Conclusions: </strong>Ladies finger water or fenugreek seeds water can be used as adjunct along with OAD to control type 2 diabetes mellitus.</p><p><strong> </strong></p>

scholarly journals Blood Glucose – Lowering Potentials of Annona muricata Leaf Extract in Alloxan–Induced Diabetic Rats

2021 ◽  
Vol 2 (2) ◽  
pp. 106-113
Author(s):  
P. O. Opara ◽  
V. H. A. Enemor ◽  
F. U. Eneh ◽  
F. C. Emengaha
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Leaf Extract ◽  
Phytochemical Analysis ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Group 6 ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

The blood glucose- lowering potentials of ethanol leaf extract of Annona muricata were studied. Thirty wistar albino rats were divided into six groups of five rats per group. Group 1 served as “Normal control” animals and received normal rat pellets and water. Diabetes mellitus was induced in Groups 2, 3, 4, and 5 by intraperitoneal injection of alloxan (130 mg/kg). Group 6 rats were administered with 400 mg/kg daily of the extract without induction; group 3 rats were treated with glibenclamide (5 mg/kg body weight), groups 4 and 5 received 200 mg/kg and 400 mg/kg body weight of A. muricata leaf extract daily respectively throughout the duration of the experiment of 14 days. Group 2 rats were induced but not treated with any drug, thus it served as the “Negative control” group. Quantitative phytochemical analysis of the leaf extract was carried out using the Association of Official Analytical Chemists (AOAC) methods. Acute toxicity test of the leaf extract of A. muricata was determined using 12 rats by Lorke’s toxicity testing method. The blood glucose levels of the animals in each group were determined using Accu-chek test strip method. The weights of the animals were determined using a standard electronic weighing balance. The result of the quantitative phytochemical analysis of the leaf showed that the ethanol leaf extract contains the following: phenols (74 mg/100 g), flavonoids (3.70 mg/100 g), tannins (2.95 mg/100 g), oxalate (6.48 mg/100 g), terpenoid (13.88 mg/100 g), phytates (130 mg/100 g), saponins (6800 mg/100 g), alkaloids (570 mg/100 g), cardiac glycoside (1690 mg/100g). Acute toxicity studies showed that LD50 was 3807.89 mg/kg body weight. The results of the average blood glucose levels (mg/dl) of the rats in each group were group 1, 82.6071±7.7524, group 2, 309.3571±163.6923, group 3, 226.7143±132.8182, group 4, 146.5000±140.1465, group 5, 150.4783±81.8340, and group 6, 83.4643±12.5329 for each group respectively. The average body weights of the rats in each group were group 1, 192.8571±22.5844, group 2, 185.7143±33.6759, group 3, 177.1429±36.67500, group 4, 219.2857±21.2908, group 5, 119.5455±23.5993, and group 6, 191.7857±25.2475. The findings from this study suggest that ethanolic leaf extract of A. muricata has notable effect in lowering blood glucose levels in diabetic rats and is a more potent drug in the treatment and management of diabetes mellitus and oxidative stress- related diseases.

scholarly journals Clinical Outcomes of Non-diabetic COVID-19 Patients with Different Blood Glucose Levels: A Nationwide Turkish Study (TurCoGlycemia)

2021 ◽  
Author(s):  
Cem Haymana ◽  
Ibrahim Demirci ◽  
Ilker Tasci ◽  
Erman Cakal ◽  
Serpil Salman ◽  
...  
Keyword(s):  
Mechanical Ventilation ◽  
Blood Glucose ◽  
Diabetic Patients ◽  
Icu Admission ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Group 3 ◽  
Group 2 ◽  
Health Database ◽  
Group 1

Abstract Purpose New coronavirus disease 2019 (COVID-19) has a worse prognosis in patients with diabetes. However, there are insufficient data about the effect of hyperglycemia on COVID-19 prognosis in non-diabetic patients. This study aimed to investigate the relationship between random blood glucose levels measured at the time of diagnosis and prognosis of COVID-19 disease in non-diabetic patients. Methods A nationwide retrospective cohort of non-diabetic patients with confirmed COVID-19 infection from 11 March to 30 May 2020 in the Turkish Ministry of Health database was investigated. The patients were stratified into three groups according to blood glucose levels which were <100 mg/dL in group-1, in the range of 100-139 mg/dl in group-2, and the range of 140-199 mg/dl in group-3. Clinical characteristics and outcomes were compared among the groups. The primary outcome was mortality. Results A total of 12,817 non-diabetic patients (median age [IQR]: 44 [25] years, females: 50.9%) were included. Patients in group-2 (5%) and group-3 (14%) had higher mortality rates than patients in group-1 (2.1%). The rates of hospitalization, hospital stays longer than 8 days, intensive care unit (ICU) admission, ICU stay more than 6 days, and mechanical ventilation were also significantly higher in group-3 patients. Likewise, glucose levels in the range of 140-199 mg/dL were an independent associate of mortality and composite of ICU admission and/or mechanical ventilation. ConclusionHyperglycemia at the time of COVID-19 diagnosis is associated with poor prognosis in non-diabetic patients. Clinicians should be more careful in the treatment of non-diabetic COVID-19 patients with hyperglycemia.

scholarly journals Estimation and correlation of serum and salivary glucose and immunoglobulin A levels and salivary candidal carriage in diabetic and non-diabetic patients

2020 ◽  
Vol 14 (4) ◽  
pp. 206-213
Author(s):  
Shruthi S Hegde ◽  
Atul P Sattur ◽  
Anil Bapu Bargale ◽  
Gayathri S Rao ◽  
Rajeeth S Shetty ◽  
...  
Keyword(s):  
Oral Candidiasis ◽  
Agar Plate ◽  
Serum Glucose ◽  
Diabetic Patients ◽  
Salivary Iga ◽  
Glucose Levels ◽  
Serum Iga ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

Background. A correlation has been noted between diabetes mellitus (DM) and changes in the oral cavity. The present study aimed to estimate, compare, and correlate serum and salivary glucose and IgA levels and salivary candidal carriage in diabetic and non-diabetic individuals. Methods. Eighty-eight subjects were categorized into three groups: group 1 (controlled DM; n=27), group 2 (uncontrolled DM; n=32) and group 3 (non-diabetics; n=29). Serum and salivary glucose levels were estimated by glucose oxidase/peroxidase method, serum and salivary IgA by a diagnostic kit, and candidal colonization by inoculating samples into Sabouraud dextrose agar plate. Statistical analyses were carried out by one-way ANOVA, post hoc Tukey tests, and Pearson’s correlation coefficient. Results. Significant elevation of serum IgA levels was observed in group 2 compared to group 3 and significant decreases in salivary IgA levels in groups 1 and 2. The candidal carriage was significantly higher in group 2 compared to group 3. Serum glucose and salivary IgA levels showed a significant correlation in group 1. There was a positive correlation between serum/ salivary glucose and serum/salivary IgA levels in group 2. In addition, there was a significant correlation between serum glucose and serum IgA levels in group 3. Conclusion. Saliva could be a potential, non-invasive diagnostic tool to estimate glucose levels. The evaluation of salivary components, like IgA, might be useful in diagnosing and managing oral manifestations in diabetic individuals. Elevated salivary glucose levels contribute to elevated candidal carriage, making individuals susceptible to oral candidiasis.

Early Troponin I Levels in Newborns Undergoing Therapeutic Hypothermia for Hypoxic Ischemic Encephalopathy and Residual Encephalopathy at Discharge

2020 ◽  
Author(s):  
Upender K. Munshi ◽  
Meredith Monaco Brown ◽  
Kate A. Tauber ◽  
Michael J. Horgan
Keyword(s):  
Therapeutic Hypothermia ◽  
Predictive Value ◽  
Troponin I ◽  
Retrospective Chart Review ◽  
Hypoxic Ischemic Encephalopathy ◽  
Mri Findings ◽  
Group 3 ◽  
Group 2 ◽  
Ischemic Encephalopathy ◽  
Group 1

Objective Elevation of serum troponin I has been reported in newborns with hypoxic ischemic encephalopathy (HIE), but it is diagnostic and prognostic utility for newborn under 6 hours is not clear. Study the predictive value of early serum troponin I levels in newborns with HIE undergoing therapeutic hypothermia (TH) for persistent residual encephalopathy (RE) at discharge. Study Design Retrospective chart review of newborns admitted with diagnosis of HIE to neonatal intensive care unit (NICU) for TH over a period of 3 years. Troponin levels were drawn with the initial set of admission laboratories while initiating TH. Newborns were followed up during hospital course and stratified into three groups based on predischarge examination and their electrical encephalography and cranial MRI findings: Group 1: no RE, Group 2: mild-to-moderate RE, and Group 3: severe RE or needing assisted medical technology or death. Demographic and clinical characteristics including troponin I levels were compared in each group. Results Out of 104 newborns who underwent TH, 65 infants were in Group 1, 26 infants in Group 2, and 13 newborns in Group 3. All groups were comparable in demographic characteristics. There was a significant elevation of serum troponin in group 2 (mild-to-moderate RE) and group 3 (severe RE) as compared with group 1 (no RE). Receiver operator curve analysis for any RE (groups 2 and 3) compared with group 1 (no RE as control) had 0.88 (0.81–0.95) area under curve, p < 0.001. A cut-off level of troponin I ≥0.12 µg/L had a sensitivity of 77% and specificity of 78% for diagnosis of any RE, positive predictive value of 68%, and a negative predictive value of 84%. Conclusion In newborns undergoing TH for HIE, the elevation of troponin within 6 hours of age predicts high risk of having RE at discharge. Key Points

scholarly journals High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome

2021 ◽  
Vol 12 ◽  
Author(s):  
Wenjun Wang ◽  
Zhonglin Chai ◽  
Mark E. Cooper ◽  
Paul Z. Zimmet ◽  
Hua Guo ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Diabetes Group ◽  
Icu Admission ◽  
Group 4 ◽  
Diabetic Status ◽  
History Of ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

BackgroundWe aimed to understand how glycaemic levels among COVID-19 patients impact their disease progression and clinical complications.MethodsWe enrolled 2,366 COVID-19 patients from Huoshenshan hospital in Wuhan. We stratified the COVID-19 patients into four subgroups by current fasting blood glucose (FBG) levels and their awareness of prior diabetic status, including patients with FBG&lt;6.1mmol/L with no history of diabetes (group 1), patients with FBG&lt;6.1mmol/L with a history of diabetes diagnosed (group 2), patients with FBG≥6.1mmol/L with no history of diabetes (group 3) and patients with FBG≥6.1mmol/L with a history of diabetes diagnosed (group 4). A multivariate cause-specific Cox proportional hazard model was used to assess the associations between FBG levels or prior diabetic status and clinical adversities in COVID-19 patients.ResultsCOVID-19 patients with higher FBG and unknown diabetes in the past (group 3) are more likely to progress to the severe or critical stage than patients in other groups (severe: 38.46% vs 23.46%-30.70%; critical 7.69% vs 0.61%-3.96%). These patients also have the highest abnormal level of inflammatory parameters, complications, and clinical adversities among all four groups (all p&lt;0.05). On day 21 of hospitalisation, group 3 had a significantly higher risk of ICU admission [14.1% (9.6%-18.6%)] than group 4 [7.0% (3.7%-10.3%)], group 2 [4.0% (0.2%-7.8%)] and group 1 [2.1% (1.4%-2.8%)], (P&lt;0.001). Compared with group 1 who had low FBG, group 3 demonstrated 5 times higher risk of ICU admission events during hospitalisation (HR=5.38, 3.46-8.35, P&lt;0.001), while group 4, where the patients had high FBG and prior diabetes diagnosed, also showed a significantly higher risk (HR=1.99, 1.12-3.52, P=0.019), but to a much lesser extent than in group 3.ConclusionOur study shows that COVID-19 patients with current high FBG levels but unaware of pre-existing diabetes, or possibly new onset diabetes as a result of COVID-19 infection, have a higher risk of more severe adverse outcomes than those aware of prior diagnosis of diabetes and those with low current FBG levels.

scholarly journals Glucose Level Estimation in Diabetes Mellitus By Saliva: A Bloodless Revolution

2015 ◽  
Vol 53 (3) ◽  
pp. 248-252 ◽  
Author(s):  
Vidya Kadashetti ◽  
Rajendra Baad ◽  
Neelima Malik ◽  
K.M. Shivakumar ◽  
Nupura Vibhute ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Glucose Level ◽  
Plasma Glucose ◽  
Diabetic Patients ◽  
Healthy Population ◽  
Glucose Levels ◽  
Whole Saliva ◽  
Group 2 ◽  
Set Up ◽  
Group 1

Abstract Background. Diabetes mellitus is a massive, growing, silent epidemic that has the potential to cripple health services in all parts of the world. Currently, a diagnosis of diabetes is achieved by evaluating plasma glucose levels. Saliva offers some distinctive advantages. Whole saliva can be collected non-invasively and by individuals with limited training. The present study was aimed to estimate and correlate the plasma and salivary glucose levels in diabetic and non diabetic subjects, with special reference to age. Method. The study population consisted of three groups: Group 1 consisted of diabetics with BGL>200mg/dl and Group 2 consisted of diabetics with BGL 130-200mg/dl based on their random plasma glucose levels. Group 3 consisted of healthy population as controls with BGL <130 mg/dl. 2 ml of peripheral blood was collected for the estimation of random plasma glucose levels and unstimulated saliva was collected for the estimation of salivary glucose Results. The salivary glucose levels were significantly higher in group 1 and group 2 diabetics when compared with controls. The salivary glucose levels show a significant correlation with plasma glucose levels between study populations, suggesting that salivary glucose levels can be used as a monitoring tool for predicting glucose level in diabetic patients. Conclusion. The present study found that estimation of salivary glucose levels can be used as a noninvasive, painless technique for the measurement of diabetic status of a patient in a dental set up.

Syphilis Immunoassay Signal Strength Correlates with Active Infection in Pregnant Women

2020 ◽  
Vol 37 (07) ◽  
pp. 671-678
Author(s):  
Amanda C. Zofkie ◽  
Angela R. Seasely ◽  
Donna Gaffney ◽  
Vanessa L. Rogers ◽  
Donald D. Mcintire ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Congenital Syphilis ◽  
Signal Strength ◽  
Clinical Staging ◽  
Group 4 ◽  
Group 3 ◽  
Group 2 ◽  
Active Syphilis ◽  
Particle Agglutination ◽  
Group 1

Abstract Objective This study aimed to evaluate the association of ARCHITECT chemiluminescent immunoassay (CIA) signal strength (signal-to-cutoff [S/CO] ratio), with maternal syphilis stage, rapid plasma reagin (RPR) reactivity, and congenital syphilis. Study Design A prospective observational study of reverse syphilis screening was conducted. Pregnant women were screened with CIA. Reactive CIA was reflexed to RPR; particle agglutination test (Treponema pallidum particle agglutination [TPPA]) was performed for CIA+/RPR− results. Clinical staging with history and physical was performed, and disease stage was determined. Prior treatment was confirmed. We compared S/CO ratio and neonatal outcomes among the following groups: Group 1: CIA+/RPR+/TPPA+ or CIA+/RPR−/TPPA+ with active syphilis; Group 2: CIA+/RPR−/TPPA+ or CIA+/serofast RPR/TPPA+, previously treated; Group 3: CIA+/RPR−/TPPA+, no history of treatment or active disease; Group 4: CIA+/RPR−/TPPA−, false-positive CIA. Results A total of 144 women delivered with reactive CIA: 38 (26%) in Group 1, 69 (48%) in Group 2, 20 (14%) in Group 3, and 17 (12%) in Group 4. Mean (±standard deviation) S/CO ratio was 18.3 ± 5.4, 12.1 ± 5.3, 9.1 ± 4.6, and 1.9 ± 0.8, respectively (p < 0.001). Neonates with overt congenital syphilis occurred exclusively in Group 1. Conclusion Women with active syphilis based on treatment history, clinical staging, and laboratory indices have higher CIA S/CO ratio and are more likely to deliver neonates with overt evidence of congenital syphilis.

A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 7001-7001 ◽  
Author(s):  
Tibor Kovacsovics ◽  
Moshe Yair Levy ◽  
Rachel J. Cook ◽  
Jonathan E. Kolitz ◽  
Peter Westervelt ◽  
...  
Keyword(s):  
Standard Therapy ◽  
Randomized Study ◽  
Dose Finding ◽  
Newly Diagnosed ◽  
Platelet Factor ◽  
Elderly Aml ◽  
Group 3 ◽  
Group 2 ◽  
Poor Outcomes ◽  
Group 1

7001 Background: Elderly AML patients have poor outcomes irrespective of therapy. CX-01 is a low anticoagulant heparin derivative that retains heparin’s ability to alter the activity of the CXCL12/CXCR4 axis, P-selectin, extracellular histones, and Platelet Factor 4. A pilot study of CX-01 combined with standard therapy for AML led to a complete remission (CR) rate of 92% ( Blood Adv 2:381, 2018). We conducted a randomized, dose-finding study of the same combination in newly diagnosed elderly AML patients. Methods: 76 fit patients older than 59 were randomized to induction with idarubicin and cytarabine on a 7+3 schedule only (Group 1); 7+3 with a lower dose of CX-01 (0.125 mg/kg/hour) (Group 2); or 7+3 with a higher dose of CX-01 (0.25 mg/kg/hour) (Group 3). Patients in CR received consolidation therapy consisting of up to 3 cycles of intermediate dose cytarabine (1000 mg/m2 every 12 hours on Days 1, 3, 5) without or with the same dose of CX-01 for Groups 1, 2, and 3, respectively. CX-01 was given as a continuous infusion after a 4 mg/kg bolus until completion of chemotherapy. Results: 66 of 75 treated patients were evaluable for response. Ten patients were not evaluable due to withdrawal of consent (6 patients), introduction of midostaurin after its approval (3 patients), or death due to hepatic sinusoidal obstructive disease at Day 21 (1 patient in Group 2). We present results for evaluable patients and not on an intent to treat basis. Baseline characteristics were similar across groups. The composite CR rate (CR + CRi) was highest for patients in Group 3 with 89% patients achieving a composite CR as compared to 58% and 50% in Groups 1 and 2, respectively. Kaplan-Meier curves indicated a statistically significant improvement in event free survival (EFS) (P = 0.019) and a non-significant trend (P = 0.10) to improvement in OS in Group 3 as compared to Group 1. Groups 1 and 2 were comparable for EFS and OS. CX-01 was well tolerated without increased incidence of bleeding in Groups 2 and 3. Conclusions: The encouraging CR rate and EFS in elderly fit patients with newly diagnosed AML suggests that CX-01 may potentiate the efficacy of standard AML induction therapy. A randomized study to confirm these findings with the higher dose of CX-01 is warranted. Clinical trial information: NCT02873338.

FA05.02: AN ANALYSIS OF SURVIVAL TRENDS IN 471 PATIENTS AFTER ESOPHAGECTOMY FOR ESOPHAGEAL ADENOCARCINOMA

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 9-10
Author(s):  
Michal Lada ◽  
Christian Peyre ◽  
Joseph Wizorek ◽  
Thomas Watson ◽  
Jeffrey Peters ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Therapy ◽  
Esophageal Adenocarcinoma ◽  
Clinical Staging ◽  
Early Stage Disease ◽  
Pet Ct ◽  
Group 3 ◽  
Group 2 ◽  
The Impact ◽  
Group 1

Abstract Background Five-year survival after the surgical treatment of esophageal cancer has traditionally been reported to be as low as 15%. More recently, the improvement of clinical staging involving PET/CT and the introduction of neoadjuvant chemo-radiation have each altered the survival outcomes of patients with this lethal disease. The impact of these factors on survival trends has not been well described in literature. The aim of this study was to analyze the survival trends after esophagectomy for esophageal adenocarcinoma at a high-volume center. Methods The study population consisted of 471 consecutive patients undergoing esophagectomy for esophageal adenocarcinoma at a university-based medical center between January 1, 2000 and July 31, 2017. Clinical variables were collected for three groups based on the date of esophagectomy and were compared (Group 1: 2000–2004, Group 2: 2005–2011, Group 3: 2012–2017). Survival was compared via the Kaplan-Meier (KM) method. Results The 471 patients had a median age of 64.0 years (range 27.0–86.2) and 395/471 (84%) were male. Dysphagia (282/471, 60%), heartburn (63/471, 13%) and chest pain (29/471, 6%) were the most common presenting symptoms. The majority of the patients underwent transhiatal esophagectomy (n = 279, 59.1%) and en-bloc esophagectomy (n = 85, 18.0%). Staging with PET/CT was utilized in 316/471 patients (67%) with 6% of Group 1, 76% of Group 2 and 100% of Group 3, P < 0.001. Neoadjuvant therapy was utilized in 44% of patients, 209/357 (0% of Group 1, 45% of Group 2 and 76% of Group 3, P < 0.001). The median survival for the entire cohort was 30.0 months (range 0.3–208.0) with 5-year KM survival of 30% for Group 1, 43% for Group 2 and 47% for Group 3, P < 0.001, Figure. When comparing Group 1 and Group 2, the 10-year KM survival improved from 23% to 37%, P < 0.001. Conclusion This analysis reveals an improvement in 5-year survival after esophagectomy from 30% to 47% over the past two decades. Similarly, 10-year survival has improved from 23% to 37%. The evolution of better clinical staging and advancements in neoadjuvant therapy likely played a vital role in these trends. In contrast to the earliest cohort, PET/CT is now routinely utilized in the staging of esophageal cancer. Further, other than those with early stage disease, all patients are currently evaluated for neoadjuvant chemo-radiation. Notably, the 5-year survival rate for the most recent cohort (2012–2017) approaches 50% and would likely be higher if patients with esophageal adenocarcinoma treated endoscopically were included. Improvements in staging and treatment paradigms for esophageal adenocarcinoma have resulted in significant progress towards cure. Disclosure All authors have declared no conflicts of interest.

Sign in / Sign up

Export Citation Format

Share Document